Check-Cap Ltd. (CHEK): Price and Financial Metrics


Check-Cap Ltd. (CHEK): $0.33

0.00 (0.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CHEK Stock Price Chart Interactive Chart >

Price chart for CHEK

CHEK Price/Volume Stats

Current price $0.33 52-week high $1.58
Prev. close $0.33 52-week low $0.29
Day low $0.32 Volume 177,000
Day high $0.34 Avg. volume 919,839
50-day MA $0.35 Dividend yield N/A
200-day MA $0.61 Market Cap 32.11M

Check-Cap Ltd. (CHEK) Company Bio


Check-Cap Ltd. is a clinical stage medical diagnostics company engaging in the development of ingestible imaging capsule system for colorectal cancer screening. The company was founded by Yoav Kimchy in April 2005 and is headquartered in Isfiya, Israel.


CHEK Latest News Stream


Event/Time News Detail
Loading, please wait...

CHEK Latest Social Stream


Loading social stream, please wait...

View Full CHEK Social Stream

Latest CHEK News From Around the Web

Below are the latest news stories about Check-Cap Ltd that investors may wish to consider to help them evaluate CHEK as an investment opportunity.

Check-Cap Ltd. Announces $10 Million Registered Direct Offering

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 20,000,000 of the Company's ordinary shares and acc

Yahoo | March 1, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM), Intercept Pharma (ICPT) and Check-Cap (CHEK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research Report), Intercept Pharma (ICPT – Research Report) and Check-Cap (CHEK – Research Report). Axsome Therapeutics (AXSM) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics today and set a price target of $180.00. The company's shares closed last Monday at $30.52. According to TipRanks.

Brian Anderson on TipRanks | February 8, 2022

Check-Cap Announces FDA Approval of Amended IDE Application for Pivotal Study of C-Scan

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for its amended Investigational Device Exemption (IDE) application, enabling initiation of th

Yahoo | February 7, 2022

Check-Cap (CHEK) Receives a Hold from Dawson James

Dawson James analyst Jason Kolbert maintained a Hold rating on Check-Cap (CHEK – Research Report) on December 16. The company's shares closed last Tuesday at $0.66, close to its 52-week low of $0.31. According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Check-Cap with a $3.00 average price target.

Christine Brown on TipRanks | January 5, 2022

Check-Cap Issues Letter to Shareholders

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today issued the following letter from its chief executive officer, Alex Ovadia, to its shareholders and the investment community:

Yahoo | January 5, 2022

Read More 'CHEK' Stories Here

CHEK Price Returns

1-mo N/A
3-mo -14.95%
6-mo -51.09%
1-year -78.15%
3-year -84.43%
5-year -98.58%
YTD -51.09%
2021 46.67%
2020 -73.26%
2019 -20.00%
2018 -79.41%
2017 -62.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5275 seconds.